Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.93 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.81 |
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343543 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3341750 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3348385 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3250371 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3350695 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3343527 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3348348 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL3341730 | 1.00 | CYP3A4 (0.93) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Hydrochloric Acid SCHEMBL3298359 | 0.99 | CYP3A4 (0.91) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Hydrochloric Acid SCHEMBL3298333 | 0.99 | CYP3A4 (0.91) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321263-A2 | COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2018-05-16 | — | — | EP | claimed |
| EP-3042901-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) | 2018-01-24 | — | — | EP | claimed |
| EP-3042901-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-07-13 | — | — | EP | claimed |
| EP-2784075-B1 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-03-23 | — | — | EP | claimed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | claimed |
| EP-2784075-A1 | Hepatitis C virus inhibitors | Bristol-Myers Squibb Company (US) | 2014-10-01 | — | — | EP | claimed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | claimed |
| US-20140050695-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-20 | — | — | US | claimed |
| US-8329159-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-11 | — | — | US | claimed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | claimed |
| US-20230235290-A1 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | UNIV ALBERTA (CA) | 2023-07-27 | — | — | US | disclosed |
| US-11591570-B2 | Recombinant cardiomyocytes and cardiomyocyte cell lines expressing hERG | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-02-28 | — | — | US | disclosed |
| US-20200181577-A1 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-06-11 | — | — | US | disclosed |
| EP-3321263-A2 | COMPOUNDS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3042901-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) | 2018-01-24 | — | — | EP | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20090041716-A1 | CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| WO-2009020828-A1 | CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020825-A1 | PROCESS FOR SYNTHESIZING COMPOUNDS USEFUL FOR TREATING HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041716-A1 | CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1((2S)-2-((METHOXYCARBONYL)AMINO)-3-METHYLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT | CPS1, PYGL, HCCS | CYP3A4 1273/4885CYP2C9 1951/4885KCNH2 2110/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885CYP2C9 2585/4885KCNH2 4523/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885CYP2C9 2585/4885KCNH2 4523/4885 |
| US-20230235290-A1 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | TNNI3, MYLK2, TNNT2 | CYP3A4 3138/4885CYP2C9 1927/4885KCNH2 10/4885 |
| US-20200181577-A1 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | TNNI3, MYLK2, TNNT2 | CYP3A4 3138/4885CYP2C9 1927/4885KCNH2 10/4885 |
| US-11591570-B2 | Recombinant cardiomyocytes and cardiomyocyte cell lines expressing hERG | KCNJ2, KCNH2, KCNE1 | CYP3A4 1304/4885CYP2C9 768/4885KCNH2 2/4885 |
| US-20140050695-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885CYP2C9 2585/4885KCNH2 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.